Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,709 GBX | +0.20% | +2.08% | +17.82% |
Mar. 28 | GSK : Sell rating from JP Morgan | ZD |
Mar. 28 | U.S. FDA approves Akebia's anemia drug | RE |
Sales 2024 * | 31.54B 39.79B | Sales 2025 * | 33.44B 42.2B | Capitalization | 69.81B 88.09B |
---|---|---|---|---|---|
Net income 2024 * | 5.6B 7.07B | Net income 2025 * | 6.25B 7.89B | EV / Sales 2024 * | 2.61 x |
Net Debt 2024 * | 12.51B 15.79B | Net Debt 2025 * | 9.38B 11.83B | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
12.5
x | P/E ratio 2025 * |
11
x | Employees | 70,212 |
Yield 2024 * |
3.59% | Yield 2025 * |
3.88% | Free-Float | 92.08% |
Latest transcript on GSK plc
1 day | +0.20% | ||
1 week | +2.08% | ||
Current month | +2.64% | ||
1 month | +2.32% | ||
3 months | +16.93% | ||
6 months | +14.36% | ||
Current year | +17.82% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +6.77% | - | |
2.51% | 4 M€ | +8.68% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,709 | +0.20% | 9,621,623 |
24-03-27 | 1,705 | +0.44% | 4,757,690 |
24-03-26 | 1,698 | +0.19% | 7,986,785 |
24-03-25 | 1,695 | +0.46% | 6,432,415 |
24-03-22 | 1,687 | +0.78% | 10,423,830 |
Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.82% | 88.25B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |